Markus Bergmann is an accomplished leader in the biotechnology and automotive industries with a rich history of strategic roles. Currently serving as the Global Head of Personalized Cancer Vaccines at CureVac since 2022, Markus focuses on developing transformative mRNA medicines. Prior to this, Markus held several key positions at ZF Group, including Managing Director of CureVac RNA Printer GmbH and Site Head at ZF Getriebe Brandenburg GmbH, overseeing finance, controlling, and IT functions. Markus's experience also includes significant roles at Rolls-Royce plc and MTU Friedrichshafen GmbH, where responsibilities encompassed strategy, performance management, and product development. An early career at McKinsey & Company involved consulting in the automotive, assembly, and healthcare sectors, while medical training at the University of Tuebingen and advanced education at prestigious institutions like Heidelberg University and Duke University laid a foundation in medicine and cancer research.
This person is not in any teams
This person is not in any offices